Methotrexate, vinblastine, epidoxorubicin and cisplatin (M-VEC) in patients with locally advanced transitional bladder cancer.

A Frassoldati, M Federico, F Barbieri, M Brausi, C Pollastri, G Berri, G Castagnetti, P P Palladini, V Silingardi
{"title":"Methotrexate, vinblastine, epidoxorubicin and cisplatin (M-VEC) in patients with locally advanced transitional bladder cancer.","authors":"A Frassoldati,&nbsp;M Federico,&nbsp;F Barbieri,&nbsp;M Brausi,&nbsp;C Pollastri,&nbsp;G Berri,&nbsp;G Castagnetti,&nbsp;P P Palladini,&nbsp;V Silingardi","doi":"10.1007/BF02988861","DOIUrl":null,"url":null,"abstract":"<p><p>M-VEC (methotrexate, vinblastine, epidoxorubicin and cisplatin), a new combined drug regimen in which epidoxorubicin has been substituted to adriamycin to reduce the toxicity of the original M-VAC chemotherapy, has been tested in 23 patients with locally advanced transitional cell bladder cancer (TCBC) (stage T2-T4 No Mo). After two to four courses, an objective response was observed in 19 patients, with 13 clinical complete responses. Seven patients underwent cystectomy after chemotherapy: one patient had no residual tumor on bladder specimens, five patients had a surgical eradication of the disease, while one patient had only a partial resection. Eight relapses of bladder carcinoma were observed, three among the surgically treated patients and five among patients who did not undergo cystectomy, with a median time-to-relapse of 9.7 months. Progression-free survival at 24 months was 52.3%. M-VEC regimen appears to be effective in locally advanced TCBC, with acceptable toxicity.</p>","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"8 2","pages":"99-103"},"PeriodicalIF":0.0000,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02988861","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical oncology and tumor pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF02988861","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

M-VEC (methotrexate, vinblastine, epidoxorubicin and cisplatin), a new combined drug regimen in which epidoxorubicin has been substituted to adriamycin to reduce the toxicity of the original M-VAC chemotherapy, has been tested in 23 patients with locally advanced transitional cell bladder cancer (TCBC) (stage T2-T4 No Mo). After two to four courses, an objective response was observed in 19 patients, with 13 clinical complete responses. Seven patients underwent cystectomy after chemotherapy: one patient had no residual tumor on bladder specimens, five patients had a surgical eradication of the disease, while one patient had only a partial resection. Eight relapses of bladder carcinoma were observed, three among the surgically treated patients and five among patients who did not undergo cystectomy, with a median time-to-relapse of 9.7 months. Progression-free survival at 24 months was 52.3%. M-VEC regimen appears to be effective in locally advanced TCBC, with acceptable toxicity.

甲氨蝶呤、长春花碱、依多柔比星和顺铂(M-VEC)在局部晚期移行性膀胱癌患者中的应用。
M-VEC(甲氨蝶呤、长春花碱、epidoxorubicin和顺铂)是一种新的联合用药方案,以epidoxorubicin取代阿霉素,以降低原来的M-VAC化疗的毒性,已在23例局部晚期移行细胞膀胱癌(T2-T4 No Mo)患者中进行了试验。经过2 ~ 4个疗程后,19例患者客观缓解,13例临床完全缓解。7例患者化疗后行膀胱切除术:1例患者膀胱标本未见肿瘤残留,5例患者手术根除,1例患者仅部分切除。8例膀胱癌复发,其中3例发生在手术治疗的患者中,5例发生在未行膀胱切除术的患者中,中位复发时间为9.7个月。24个月无进展生存率为52.3%。M-VEC方案似乎对局部晚期TCBC有效,毒性可接受。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信